I am a veterinarian with postgraduate training in epidemiology (MSc & PhD) and GIS
(MSc); expertise in epidemiological, clinical and implementation studies in tropical
diseases, in particular visceral leishmaniasis in the Indian subcontinent and human
African trypanosomiasis in sub-Saharan Africa. In the last 10 years I have been
working to develop and evaluate new tools to prevent, diagnose and treat tropical
diseases around the world. I have worked in various capacities at the Institute of
Tropical Medicine (ITM) in Belgium, the London School of Hygiene and Tropical
Medicine (LSHTM) in the United Kingdom and the Barcelona Institute for Global Health
(ISGlobal) in Spain. I am currently a Senior Scientific Officer for the Neglected Tropical
Diseases program at the Foundation for Innovative New Diagnostics (FIND)
Clinical doctor. Master in Tropical Medicine and Community Medicine. Since 1999 working on Chagas projects in various countries in the region. Honduras, Guatemala, Bolivia and Paraguay with MSF. Since 2015 responsible for the access projects for DNDi Latin America.
Colin Forsyth is a medical anthropologist and epidemiologist who joined DNDi in March, 2016 to help
launch the U.S. Chagas Treatment Access project. In the 1990’s, he lived in Bolivia and became
acquainted with the devastating impact of Chagas disease. In 2013, he conducted anthropology research
on Chagas disease at a nonprofit clinic in Bolivia where more than half of the patient population was
infected with Trypanosoma cruzi, the pathogen that causes the disease. He investigated the beliefs,
experiences, and treatment strategies of patients dealing with Chagas disease, and identified key
barriers that hampered access to healthcare. Since joining DNDi, he has collaborated in several research
projects with DNDi’s partner, the Center of Excellence for Chagas Disease at Olive View-UCLA Medical
Center. This research has focused on identifying barriers to diagnosis and treatment for Chagas disease
patients in the United States. He also manages the Chagas Research Platform and supports DNDi’s
Chagas disease access projects in Latin America. He completed an M.P.H in Epidemiology in 2011, and a
Ph.D. in Applied Anthropology in 2014, at the University of South Florida, Tampa.
Eric Chatelain graduated with a PhD in Biochemistry in 1993 at the INSA Lyon, France.
Following 5 years in the academia (ICRF, London, UK and FMI/Novartis, Basel, Switzerland) as a
Research Fellow, he joined the pharmaceutical industry (Spirig Pharma AG, Switzerland) in
1999. Focus was on Dermatology R&D and Eric Chatelain led the Biopharmacy Research Lab
(till 2003) before heading the Pre-clinical Department (till 2007). His activities led to major
projects being taken on board for further clinical development.
Since joining DNDi (Drugs for Neglected Diseases initiative) in 2007, Eric’s main role is the
management of various projects/teams around the world working on the development of new
drugs for neglected diseases. Under his leadership up to 10 preclinical candidates were
delivered for visceral Leishmaniasis (VL) and Chagas disease, some of them currently being
assessed in human. Until mid-2009 he was responsible for all screening/early discovery
activities before joining the Chagas disease team and taking on responsibility for all Chagas
discovery and preclinical projects. During that period he was responsible for the development
for high-throughput screening assay (HTS) to assess compounds for their activity against
Leishmania and T. cruzi, the pathogens involved in VL and Chagas disease respectively and led
DNDi global current effort in lead optimization for these diseases with major and recognized
institutions in Australia, Brazil, Europe and South Korea. In 2011 he played an essential role in
restructuring of DNDi lead optimization programs and now co-leads the entire DNDi lead
optimization effort. Eric is also leading DNDi Chagas Biomarkers strategy and its
implementation, as well as translational projects to improve understanding of PK/PD
relationships and more efficient transition of compounds into clinical trials.
(Português do Brasil) Médica formada pela Universidade Federal Fluminense; Residência em Clínica Médica pelo - Hospital Central da Aeronáutica; Residência em Cardiologia pelo Hospital Universitário Clementino Fraga filho da Universidade Federal do Rio de Janeiro; Pós graduada em Medicina do Exercício e do Esporte pela Universidade Estácio de Sá; Mestre em cardiologia pela UFRJ e Doutora em doenças infecciosas pela Fiocruz. Atualmente pesquisadora em doença de Chagas.
Dedicated professional with several years’ experience in pharmaceutical industry, public health and internationally recognized research institutes in Switzerland, the UK, Germany and Thailand. Interdisciplinary background in preclinical drug discovery, clinical pharmacology, pharmacometrics and epidemiology. Expertise in pharmacokinetic-pharmacodynamic modelling and simulation of drugs for neglected tropical diseases with a particular focus on Chagas disease and filarial diseases.
Israel Molina graduated in Medicine and Surgery from Universidad Autónoma de Barcelona in
1998, specializing in Internal Medicine and Infectious Diseases at the University Hospital Vall
Head of the Tropical Medicine and International Health Unit at the University Hospital Vall
d´Hebron and Director of the International Health Program at the Catalan Institute for Health
Professional experience in Equatorial Guinea, Angola and Brazil. As part of the faculty, Molina
participates in various graduate and master's courses at Universidad Autónoma de Barcelona,
Universidad de Barcelona and others, and organizes his own courses at PROSICS.
Since 2018 he has been Scientific Director of the recently launched Centro de Investigação em
Saúde de Cubal (Cubal Health Research Center) from the Katyavala Bwila University of
Benguela, where he manages various research projects.
Head of the RICET (Collaborative Tropical Disease Research Network) research group of the
Carlos III Institute, member of the Spanish Society of Infectious Diseases and Clinical Medicine
(SEIMC), the Spanish Society of Tropical Medicine and International Health (SEMTSI), and the
International Society of Travel Medicine (ISTM).
Since January 2020 he has been a senior researcher at the Oswaldo Cruz Foundation (FIOCRUZ)
of Minas Gerais, at the Rene Rachou Institute in Belo Horizonte, Brazil.
Drug Discovery Manager at DNDi Latin America. Medical Chemistry and neglected tropical diseases. Pharmacist with a Master's degree (2007) and a PhD (2011) in Pharmacy from the Federal University of Santa Catarina. Industrial experience as Research and Innovation Coordinator (2014-15) at Cristália Produtos Químicos e Farmacêuticos, managing research projects from the planning to the registration stage. International academic experience as university assistant at the Department of Pharmacognosy of the University of Vienna (2016), Visiting researcher at the Department of Pharmaceutical Sciences at Uppsala University, Sweden (2010), and visiting researcher at the Department of Pharmacognosy and Pharmaceutic Chemistry at the University of Innsbruck, Austria (2012 - 2013).
(Español) Juan Carlos Villar, es un médico internista colombiano, especialista en cardiología preventiva y doctorado en epidemiología clínica. Es docente y director de posgrado en métodos de investigación y practica Basada en evidencia en la Universidad Autónoma de Bucaramanga y dirige el centro de investigaciones de la Fundación Cardioinfantil - Instituto de Cardiologia, un centro de referencia en medicina cardiovascular en Bogotá. Ha participado en varios ensayos clínicos internacionales como investigador líder para Colombia. En enfermedad de Chagas, es el investigador principal de los estudios EQUITY (que ya finalizó su reclutamiento) y ATTACH (en desarrollo).
More than 30 years of extensive international hands-on experience in the IVD industries
(BioChem ImmunoSystems, Canada; Diagast Laboratoires, France; Innogenetics N.V., Belgium).
I have successfully managed several R&D projects throughout all stages from discovery to
regulatory processes and market introduction.
Late 2009, I co-founded INFYNITY BIOMARKERS in Lyon. The company specializes in novel
approaches for Infectious diseases diagnostics. INFYNITY BIOMARKERS team has developed
unique immunoassays products focusing on disease monitoring rather than standard
serodiagnostic. Using cutting-edge Nanofluidic technology, we can explore the antibody diversity
subsequent to infection or anti-infective therapies.
Physician, senior specialist in Internal Medicine at the International Health Service of the Hospital Clínic in Barcelona, Assistant Research Professor at ISGlobal and Associate Professor at Barcelona University. She obtained her PhD in Internal Medicine at the University of Barcelona in 2016. Her main line of research in International Health is on Chagas Disease, from basic to Public Health research. Since 2010 she is the technical coordinator of the Comprehensive Care Platform for Chagas' disease patients in Bolivia. Since 2011 he has been a member of the international network "New Tools for the Diagnosis and Evaluation of the Patient with CD (NHEPACHA)". Since 2007, she has been teaching Global Health in Masters in International Health (University of Barcelona); and Masters of One Health, and Masters Immigration, Interculturality and Health (Autonomous University of Barcelona). In 2010 she coordinated the protocol for screening and diagnosis of Chagas' disease in pregnant Latin American women (Departament de Salut, Generalitat de Catalunya). Since 2017 she is the scientific coordinator of the InSPIRES project (H2020 program), bringing science closer to society, integrating the RRI, the "open-science and open data" in its scientific approach. Since 2019 she is the co-coordinator of La Caixa LivingLab.
Pierre Buekens is W. H. Watkins Professor of Epidemiology at the School of Public Health and Tropical
Medicine and Adjunct Professor of Obstetrics and Gynecology at the School of Medicine at Tulane
University, New Orleans. He is also Director of the Center for Emerging Reproductive and Perinatal
Epidemiology (CERPE). Dr. Buekens was Dean of Tulane School of Public Health and Tropical
Medicine from 2003 to 2018. He previously was Professor and Chair of the Department of Maternal and
Child Health and Associate Dean for Global Health in the School of Public Health at The University of
North Carolina at Chapel Hill. Dr. Buekens earned his MD, MPH, and PhD degrees from the Université
Libre de Bruxelles (Free University of Brussels, Belgium). In 2010 he was awarded an Honorary
Doctorate in Medical Sciences by the University of Suriname. He is a Corresponding Member of the
Royal Academy of Medicine of Belgium and is past chair of the Board of the Consortium of Universities
for Global Health (CUGH). Dr. Buekens’ research interests are in global perinatal and reproductive
Sergio Sosa-Estani, MD, MPH, PhD, Medical Surgeon, joined DNDi in December 2016.
Sergio has performed many epidemiological and clinical research projects on tropical, endemic, re-emerging and emerging diseases as well as Chagas disease, leishmaniasis, HIV/AIDS, and other infectious diseases. He joined DNDi from the National Institute of Parasitology “Dr. Mario Fatala Chaben”, Argentinian Ministry of Health, where he occupies the position of Institute Director. Sergio is also Researcher of the National Council of Scientific and Technological Research (CONICET) in Argentina, a professor for the Master of Clinical and Health Care Effectiveness program of the University of Buenos Aires and the Master of Public Health and Master of Molecular Biology programs of the University of San Martín in Buenos Aires.